about
Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma.Mediastinal seminoma in a patient with Wiskott-Aldrich syndrome.Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.Splenosis in a patient with autoimmune thrombocytopenia.Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trialPhase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.Infiltrative cerebellar ganglioglioma: conventional and advanced MRI, proton MR spectroscopic, and FDG PET findings in an 18-month-old childBiomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG TrialCriteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.Cerebral glucose metabolism on positron emission tomography of children.Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation.Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma.Radioisotope diagnosis and therapy of malignant pheochromocytoma.Malignant pheochromocytoma: current status and initiatives for future progress.Evaluation of children with craniopharyngioma using carbon-11 methionine PET prior to proton therapyComparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcomaThe role of PET/CT in assessing pulmonary nodules in children with solid malignanciesRetrospective evaluation of PET-MRI registration algorithms.The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphomaRegional brain glucose metabolism and neurocognitive function in adult survivors of childhood cancer treated with cranial radiationPhase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupThoracic neural crest tumors in Beckwith-Wiedemann syndrome.PET imaging in pediatric oncology.Whole-Body Pediatric Neuroblastoma Imaging: 123I-mIBG and Beyond.FDG PET/CT imaging of desmoplastic small round cell tumor: findings at staging, during treatment and at follow-up.Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology GroupA practical, automated synthesis of meta-[(18)F]fluorobenzylguanidine for clinical use.Successive distinct high-grade gliomas in L-2-hydroxyglutaric aciduria.Efficient automated syntheses of high specific activity 6-[18F]fluorodopamine using a diaryliodonium salt precursorFDG positron emission tomography/computed tomography studies of Wilms' tumorPET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma.Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.PET-CT of the normal spinal cord in children.Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.Postoperative cerebral glucose metabolism in pediatric patients receiving proton therapy for craniopharyngioma.123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel.Evaluation of the biodistribution of 11C-methionine in children and young adults.Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project.The Role of 18F-FDG-PET/CT in Pediatric Sarcoma.
P50
Q33216796-9EABB970-9098-4B1B-855A-2F7D788961C4Q33345363-997E4AE0-9852-4D6B-AB9E-C4643F5BC86FQ33442162-AF2CF1B4-D78D-4627-AB33-97107DDF47EBQ33496494-B0B4C9CA-93B3-4AE0-8BBF-BC61B9646D1FQ33514216-BD70C17A-62CF-447E-8B83-4D11F1EAB5D9Q33597441-5A369A52-0559-4BFC-9E6D-7268264EEBD5Q33788788-963AF39B-5F91-4AD0-B9C3-C928FF147E49Q33789007-9EB75F0A-4904-40CE-88F9-3D7F167CBB87Q33834340-F1344C7F-8348-4714-946C-73B2805146C1Q33855135-E293AA45-0EB5-40BD-83D2-3F67784F01A2Q33887843-852DB258-D756-4958-8E4A-B413E1D55E9FQ33940794-8DEDC4B0-6C60-4EBE-A730-DA869937CA23Q34166545-58187DFC-7AF5-4F88-9156-92178E9A426DQ34432944-7663249E-0047-4BC5-BE2A-6B3F48039752Q34550903-58BD25C9-7CE6-4566-9865-92FEC8A79AAFQ34585628-65AF5CD7-14C5-4185-8820-9819C92ABA15Q34706841-8199B6EF-EC58-4B64-9546-53813D928F0FQ34769288-0619B157-DD6F-449F-B3B7-7B0A11814A44Q34970934-6968BEA1-8801-46BE-B743-BC4EC98251F4Q35152064-95F4EF81-D2A4-4343-8CC5-F3CBE1B1C950Q35198474-CED41C33-FE03-49F9-B883-2F6E205ECA37Q35511099-7AD1D61C-C61D-4526-AFB5-5A703066E8F6Q35546116-E3621620-C70C-4461-BB73-454A3CCE5120Q35639830-1429BAFD-0B21-473F-9C41-2EC4182EB0E5Q35920881-616D37B5-BC87-41DC-8E47-0C567EF29C7EQ35929022-842E8853-94B8-472D-805E-E2F277C12B85Q36089239-9420DEB7-1780-4117-9715-DBE01038AE07Q36296809-6909A60C-F0FF-4F2E-8FA2-3D3FA3AEF80FQ36311724-40810684-9D36-4522-A934-9AE1FF6341AAQ36469840-95F0BBFB-AFCF-40CF-9335-EA15784C5749Q36485366-1D2B5BDD-0E52-4039-8B3D-612492FAF0B7Q36491659-5F8464DA-26F8-4B6B-8BA2-4191B60AE9F0Q36750627-20FFB448-DF37-4516-8F6B-E22A773198C3Q36922562-1D3FD411-84C5-4CE8-A32E-27EFBF4DC776Q36927476-5419430D-BD0D-4964-A037-53FD57E2FF79Q37433334-DD5011C6-F11B-449A-8D99-C3C1AE928952Q37559805-6E082EB7-3DAB-4B43-A1CA-AC776864D4A9Q37584750-E8E07D0C-460A-409D-A487-17C5CCB20028Q37876586-864D950A-D5CE-48E9-A835-948ED43E5A04Q38729115-89C902CE-6DE1-402C-9818-55A1FBF7A413
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Barry Shulkin
@ast
Barry Shulkin
@en
Barry Shulkin
@es
Barry Shulkin
@nl
type
label
Barry Shulkin
@ast
Barry Shulkin
@en
Barry Shulkin
@es
Barry Shulkin
@nl
altLabel
barry shulkin
@en
prefLabel
Barry Shulkin
@ast
Barry Shulkin
@en
Barry Shulkin
@es
Barry Shulkin
@nl
P1053
J-6268-2018
P106
P31
P496
0000-0003-4784-7914